According to Gram Research analysis, a 2026 study found that a protein called PDE10A directly causes arteries to harden and calcify, particularly in patients with kidney disease. Blocking this protein with a drug called TAK-063 significantly reduced artery calcification in animal models, suggesting a new potential treatment approach for a serious condition that currently has limited therapeutic options.
Researchers discovered that a protein called PDE10A plays a major role in causing arteries to harden and calcify, a serious problem for people with kidney disease and poor circulation. Using lab studies and animal models, scientists found that blocking this protein with a drug called TAK-063 significantly reduced artery calcification. This discovery could lead to new treatments for a condition that currently has limited options and increases the risk of heart attacks and strokes in vulnerable patients.
Key Statistics
A 2026 research article in the Journal of the American Society of Nephrology found that PDE10A protein levels increase in calcified arteries from both patients with peripheral artery disease and in animal models of kidney disease.
In animal studies, the PDE10A inhibitor drug TAK-063 significantly reduced medial artery calcification in both vitamin D3-induced calcification models and in a 5/6 nephrectomy chronic kidney disease model.
Researchers demonstrated that blocking PDE10A markedly attenuated phosphate-induced transformation of smooth muscle cells into bone-like cells, a key mechanism driving artery calcification.
The study identified that PDE10A promotes artery calcification through activation of the p38 MAPK-MMP-3 signaling pathway, providing a mechanistic target for future drug development.
The Quick Take
- What they studied: Whether a protein called PDE10A causes arteries to become hard and calcified, and whether blocking it could prevent this problem
- Who participated: The research used human artery samples from patients with circulation problems, laboratory-grown vascular cells, and animal models of kidney disease and vitamin D toxicity
- Key finding: Blocking PDE10A with a drug called TAK-063 significantly reduced artery calcification in multiple animal models, suggesting this protein is a key driver of the hardening process
- What it means for you: This research identifies a new potential treatment target for artery calcification, a serious complication in kidney disease patients. However, human clinical trials are still needed to confirm safety and effectiveness before this becomes an available treatment
The Research Details
This was a comprehensive laboratory and animal study published in 2026 that investigated the role of PDE10A protein in artery calcification. The researchers used multiple approaches: they examined human artery tissue from patients with peripheral artery disease, studied how the protein behaves in cultured vascular cells (the smooth muscle cells that make up artery walls), and tested the effects in living animal models.
The team used several techniques to understand PDE10A’s role: they reduced the protein’s levels (knockdown), increased it (overexpression), completely removed the gene (deletion), and tested a drug called TAK-063 that blocks the protein’s activity. They also used an ex vivo model where they cultured artery rings outside the body to observe calcification in a more realistic tissue environment.
To test whether blocking PDE10A could work as a treatment, researchers evaluated TAK-063 in two different animal models of artery calcification: one using vitamin D3 injection and another using a surgical kidney disease model (5/6 nephrectomy) that mimics chronic kidney disease in humans.
This multi-layered approach is important because it moves from basic science to potential clinical application. By studying human tissue, isolated cells, and whole animals, the researchers could confirm that PDE10A’s role in calcification is consistent across different biological systems. Testing a specific drug (TAK-063) in animal models provides evidence that blocking this protein could actually work as a medical treatment, not just in theory but in living organisms with functioning immune and organ systems.
The study’s strength lies in its comprehensive design using multiple complementary approaches that confirm each other’s findings. The use of both genetic approaches (deleting the gene) and pharmacological approaches (using a drug) strengthens confidence in the results. Publication in the Journal of the American Society of Nephrology, a respected peer-reviewed journal focused on kidney and vascular disease, indicates the work met rigorous scientific standards. However, the study was conducted in laboratory and animal settings, so human clinical trials would be needed to confirm these findings apply to patients.
What the Results Show
The research demonstrated that PDE10A protein levels increase in arteries that are undergoing calcification, both in laboratory cell cultures and in actual calcified arteries from patients and animal models. When scientists reduced or blocked PDE10A, the calcification process was significantly slowed or stopped. Conversely, when they increased PDE10A levels, calcification accelerated, confirming that this protein directly drives the hardening process.
The most promising finding was that TAK-063, a drug that blocks PDE10A, effectively reduced artery calcification in two different animal models of the disease. In the vitamin D3 model, which causes rapid calcification, and in the 5/6 nephrectomy model, which mimics chronic kidney disease in humans, the drug significantly prevented or reduced calcium buildup in artery walls.
The researchers also identified the biological mechanism by which PDE10A causes calcification: it activates a signaling pathway involving p38 MAPK and MMP-3 proteins that triggers vascular smooth muscle cells to transform into bone-like cells and deposit calcium. This mechanistic understanding is important because it explains why blocking PDE10A works and could guide future drug development.
The study found that PDE10A’s effects are specific to smooth muscle cells in the artery walls, not other cell types. This is important because it suggests that blocking PDE10A might have fewer side effects than drugs that affect the protein in other tissues. The ex vivo aortic ring model confirmed that the effects observed in cell cultures and whole animals also occur in isolated artery tissue, providing additional evidence that the findings are biologically relevant.
Artery calcification has been recognized as a major problem in kidney disease for decades, but effective treatments remain limited. Previous research identified various factors that contribute to calcification, including phosphate imbalance, inflammation, and cellular transformation. This study is novel because it specifically identifies PDE10A as a critical mediator and demonstrates that blocking it can prevent calcification. The finding that phosphodiesterase inhibitors could be therapeutic targets in this context opens a new avenue for treatment, as these proteins have already proven to be effective drug targets in other diseases like heart failure and erectile dysfunction.
This study was conducted entirely in laboratory and animal models and did not include human clinical trials. Animal models, while useful for understanding disease mechanisms, don’t always perfectly predict how treatments will work in humans. The study did not specify the exact sample sizes for all experiments, making it difficult to assess statistical power. Additionally, the research focused specifically on PDE10A and didn’t compare its importance to other phosphodiesterase proteins that might also play roles in calcification. Long-term safety and efficacy data in humans would be needed before TAK-063 could be considered for clinical use.
The Bottom Line
Based on this research, PDE10A emerges as a promising new drug target for preventing artery calcification in kidney disease patients. The evidence is strong that blocking this protein reduces calcification in multiple experimental systems. However, confidence in clinical recommendations remains moderate because human trials have not yet been conducted. Patients with kidney disease or peripheral artery disease should continue following their doctor’s current treatment plans while this research progresses toward human testing.
This research is most relevant to patients with chronic kidney disease, particularly those at risk for or already experiencing artery calcification. It’s also relevant to people with peripheral artery disease (poor circulation in the legs and feet) who develop calcified arteries. Healthcare providers treating these populations should monitor developments in PDE10A-targeting drugs. People without kidney disease or circulation problems don’t need to take action based on this research at this time.
If TAK-063 or similar PDE10A inhibitors move forward to human clinical trials, it typically takes 5-10 years for a new drug to progress from animal studies to FDA approval. Patients should not expect this treatment to be available immediately, but the research suggests it could become an option within the next decade if clinical trials are successful.
Frequently Asked Questions
What causes arteries to harden and calcify in kidney disease patients?
Multiple factors contribute, including phosphate imbalance, calcium buildup, and inflammation. This 2026 research identified PDE10A protein as a critical driver that triggers vascular smooth muscle cells to transform into bone-like cells and deposit calcium in artery walls.
Is there a treatment available now for artery calcification?
Current treatments focus on managing phosphate and calcium levels through diet and medications, but no specific drug targeting artery calcification is widely available. This research identifies PDE10A inhibitors as a promising future option, though human clinical trials are still needed.
How does blocking PDE10A prevent artery calcification?
Blocking PDE10A stops activation of a signaling pathway (p38 MAPK-MMP-3) that causes vascular smooth muscle cells to transform into bone-forming cells. This prevents calcium deposition in artery walls, as demonstrated in multiple laboratory and animal models.
When will PDE10A inhibitors be available as a treatment?
The drug TAK-063 showed promise in animal studies, but human clinical trials are required before it could be approved for patient use. This typically takes 5-10 years, so availability would likely be at least several years away if trials are successful.
Who should be most concerned about artery calcification?
Patients with chronic kidney disease and those with peripheral artery disease (poor circulation) face the highest risk. These populations should work with their doctors to manage phosphate and calcium levels while monitoring for artery calcification through imaging and blood tests.
Want to Apply This Research?
- For patients with kidney disease or peripheral artery disease, track arterial health markers that your doctor monitors: phosphate levels, calcium levels, and any imaging results showing artery calcification. Record these quarterly or as recommended by your healthcare provider to monitor disease progression.
- Work with your doctor to optimize phosphate and calcium balance through diet and medications, as these are known contributors to artery calcification. Use the app to log dietary phosphate intake and medication adherence, which may help slow calcification progression while new treatments like PDE10A inhibitors are being developed.
- Set up long-term tracking of kidney function tests (eGFR, creatinine) and mineral metabolism markers (phosphate, calcium, PTH) every 3-6 months. Create reminders for imaging studies your doctor recommends to assess artery calcification status. Document any new symptoms of poor circulation to discuss with your healthcare team.
This research describes laboratory and animal studies investigating PDE10A’s role in artery calcification. While the findings are promising, human clinical trials have not yet been conducted. This article is for educational purposes and should not be interpreted as medical advice. Patients with kidney disease or peripheral artery disease should continue following their healthcare provider’s treatment recommendations and discuss any questions about new research with their doctor before making changes to their care plan. TAK-063 and other PDE10A inhibitors are not currently approved for clinical use in humans.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.